Zevra Therapeutics, Inc. (1GDA.F)
| Previous close | 4.2000 |
| Open | 4.2000 |
| Bid | 4.2000 x N/A |
| Ask | 4.2600 x N/A |
| Day's range | 4.2000 - 4.2000 |
| 52-week range | 3.8200 - 6.4500 |
| Volume | |
| Avg. volume | 17 |
| Market cap | 176.333M |
| Beta (5Y monthly) | 1.84 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.2100 |
| Earnings date | 13 May 2024 - 17 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
GlobeNewswireZevra Therapeutics Presents New Data on the Long-Term Safety and Efficacy of Arimoclomol as a Treatment for Niemann-Pick Disease Type C at the SIMD 45th Annual Meeting
The oral presentation highlighted data from Zevra’s Expanded Access Program demonstrating a consistent safety profile CELEBRATION, Fla., April 15, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a rare disease therapeutics company, today announced that new long-term real-world data from the arimoclomol expanded access program (EAP: NCT04316637) for the treatment of Niemann-Pick disease type C (NPC) was featured in an oral presentation during the Societ
- GlobeNewswire
Zevra Therapeutics Refinances Existing Debt with up to $100M in Committed Capital under New Credit Facility
CELEBRATION, Fla., April 10, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a rare disease therapeutics company, today announced that it has entered into a new credit facility provided by leading biotech investors. Led by Perceptive Advisors and Healthcare Royalty, the new credit facility provides up to $100M in committed capital in three tranches: an initial draw of $60M at closing, a second tranche of up to $20M available until October 5, 2025, and
Simply Wall St.Zevra Therapeutics Full Year 2023 Earnings: Revenues Beat Expectations, EPS Lags
Zevra Therapeutics ( NASDAQ:ZVRA ) Full Year 2023 Results Key Financial Results Revenue: US$27.5m (up 170% from FY...
